BeOne Medicines AG (ONC) News
Follow BeOne Medicines AG (ONC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
BeOne Medicines Says FDA Grants Priority Review to Brukinsa Combination
BeOne Medicines said the FDA granted priority review to a Brukinsa combination for mantle cell lymphoma.
REGULATION | Nov 04, 2026, 03:07 PM UTC
H
BeiGene Reports Q2 2026 Results: Full Earnings Call Transcript
BeiGene (NASDAQ: ONC ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered APIs. For comprehensive financial data and transcripts, visit
LIVE | Sep 17, 2026, 01:43 PM UTC
H
BeOne Medicines wins U.S. FDA approval for TEVIMBRA-based regimen
BeOne Medicines announces U.S. FDA approval for a TEVIMBRA-based regimen for first-line HER2+ GEA.
EQUITY | Aug 25, 2026, 02:46 PM UTC
L
ONC Beats Estimates
ONC reports $1.7B revenue
EARNINGS | Aug 05, 2026, 10:11 AM UTC
L
BeOne Medicines Raises FY2026 Sales Guidance from $6.300B-$6.500B to $6.600B-$6.800B vs $6.479B Est
BeOne Medicines (NASDAQ: ONC ) raises FY2026 sales outlook from $6.300 billion-$6.500 billion to $6.600 billion-$6.800 billion vs $6.479 billion estimate.
EARNINGS | Aug 05, 2026, 10:00 AM UTC
L
Beone Medicines Insider Sold Shares Worth $44,626,424, According to a Recent SEC Filing
() -- John Oyler, Director, Chief Executive Officer, on July 14, 2026, sold 145,861 shares in Beone Medicines (ONC) for $44,626,424. Following the Form 4 filing with the SEC, Oyler has control over a total of 51,477,911
REGULATION | Jul 15, 2026, 08:11 AM UTC
L
Beone Medicines Insider Sold Shares Worth $18,256,808, According to a Recent SEC Filing
() -- John Oyler, Director, Chief Executive Officer, on July 10, 2026, sold 60,218 shares in Beone Medicines (ONC) for $18,256,808. Following the Form 4 filing with the SEC, Oyler has control over a total of 51,637,304 o
REGULATION | Jul 15, 2026, 08:11 AM UTC
L
BeOne Medicines treatment of pancreatic cancer granted orphan status
BeOne Medicines' MTA-cooperative PRMT5 inhibitor was granted FDA orphan designation as a treatment of pancreatic cancer, according to a post to the agency's website. Reference Link
EQUITY | Jul 09, 2026, 02:58 PM UTC
H
BeOne Medicines price target raised to $451 from $436 at RBC Capital
RBC Capital raised the firm's price target on BeOne Medicines to $451 from $436 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has pi
RATES | Jul 07, 2026, 11:30 AM UTC
L
Curis Consents 6 Patients in Phase 2 Trial of Emavusertib in Chronic Lymphocytic Leukemia
() -- Curis (CRIS) said Monday it has consented the first six patients in a phase 2 study of emavusertib in chronic lymphocytic leukemia, or CLL, just days after opening 11 clinical sites for enrollment. The biotechnolog
EQUITY | Jul 06, 2026, 02:11 PM UTC
L
Citizens Reiterates Market Outperform on BeOne Medicines, Maintains $396 Price Target
Citizens analyst Reni J. Benjamin reiterates BeOne Medicines (NASDAQ: ONC ) with a Market Outperform and maintains $396 price target.
EQUITY | Jul 01, 2026, 01:43 PM UTC
H
BeOne Medicines Announces Topline Results From Its Phase 3 MANGROVE Study Of Foundational BTK Inhibitor Brukinsa Plus Rituximab In Adult Pat
BeOne Medicines Ltd. (NASDAQ: ONC, HKEX: 06160, SSE: 688235))), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK
EQUITY | Jun 30, 2026, 10:06 AM UTC